Literature DB >> 7543586

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

R Wyatt1, J Moore, M Accola, E Desjardin, J Robinson, J Sodroski.   

Abstract

The binding of human immunodeficiency virus type 1 (HIV-1) to the cellular receptor CD4 has been suggested to induce conformational changes in the viral envelope glycoproteins that promote virus entry. Conserved, discontinuous epitopes on the HIV-1 gp120 glycoprotein recognized by the 17b, 48d, and A32 antibodies are preferentially exposed upon the binding of soluble CD4 (sCD4). The binding of the 17b and 48d antibodies to the gp120 glycoprotein can also be enhanced by the binding of the A32 antibody. Here we constructed HIV-1 gp120 mutants in which the variable segments of the V1/V2 and V3 structures were deleted, individually or in combination, while the 17b, 48d, and A32 epitopes were retained. The effects of the variable loop deletions on the function of the HIV-1 envelope glycoproteins and on the exposure of epitopes induced by sCD4 or A32 binding to the monomeric gp120 glycoprotein were examined. The variable-loop-deleted envelope glycoproteins were able to mediate virus entry, albeit at lower efficiencies than those of the wild-type glycoproteins. Thus, the V1/V2 and V3 variable sequences contribute to the efficiency of HIV-1 entry but are not absolutely required for the process. Neither the V1/V2 nor V3 loops were necessary for the increase in exposure of the 17b/48d epitopes induced by binding of the A32 monoclonal antibody. By contrast, induction of the 17b, 48d, and A32 epitopes by sCD4 binding apparently involves a movement of the V1/V2 loops, which in the absence of CD4 partially mask these epitopes on the native gp120 monomer. The results obtained with a mutant glycoprotein containing a deletion of the V1 loop alone indicated that the contribution of the V2 loop to these phenomena was more significant than that of the V1 sequences. These results suggest that the V1/V2 loops, which have been previously implicated in CD4-modulated, postattachment steps in HIV-1 entry, contribute to CD4-induced gp120 conformational changes detected by the 17b, 48d, and A32 antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543586      PMCID: PMC189432     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  86 in total

1.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity.

Authors:  S A Tilley; W J Honnen; M E Racho; M Hilgartner; A Pinter
Journal:  Res Virol       Date:  1991 Jul-Aug

5.  Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Authors:  T K Hart; R Kirsh; H Ellens; R W Sweet; D M Lambert; S R Petteway; J Leary; P J Bugelski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

Authors:  D D Ho; M S Fung; Y Z Cao; X L Li; C Sun; T W Chang; N C Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

7.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

Authors:  K S Steimer; C J Scandella; P V Skiles; N L Haigwood
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

8.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  The transmembrane glycoprotein of human immunodeficiency virus type 1 induces syncytium formation in the absence of the receptor binding glycoprotein.

Authors:  L G Perez; M A O'Donnell; E B Stephens
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

10.  Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.

Authors:  P Westervelt; D B Trowbridge; L G Epstein; B M Blumberg; Y Li; B H Hahn; G M Shaw; R W Price; L Ratner
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more
  241 in total

1.  Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Authors:  L A Cavacini; J E Peterson; E Nappi; M Duval; R Goldstein; K Mayer; M R Posner
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Authors:  R W Sanders; L Schiffner; A Master; F Kajumo; Y Guo; T Dragic; J P Moore; J M Binley
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.

Authors:  R J Center; P L Earl; J Lebowitz; P Schuck; B Moss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Energetics of the HIV gp120-CD4 binding reaction.

Authors:  D G Myszka; R W Sweet; P Hensley; M Brigham-Burke; P D Kwong; W A Hendrickson; R Wyatt; J Sodroski; M L Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Authors:  C B Zhu; L Zhu; S Holz-Smith; T J Matthews; C H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

6.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120.

Authors:  J Dumonceaux; C Goujon; V Joliot; P Briand; U Hazan
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.

Authors:  T L Hoffman; C C LaBranche; W Zhang; G Canziani; J Robinson; I Chaiken; J A Hoxie; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

9.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Authors:  Aarti Raja; Miro Venturi; Peter Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.